Structure Therapeutics Incorporation header image

Structure Therapeutics Incorporation

GPCR

Equity

ISIN null / Valor 124807608

NASDAQ (2026-08-11)
USD 52.13-3.11%

Structure Therapeutics Incorporation
UMushroom community rating:

star star star star star
3.50 8 votes No rating yet
NegativeNeutralPositive

About company

Structure Therapeutics Incorporation leverages advanced technologies in molecular visualization, computational chemistry, and data integration to develop innovative medicines. The company focuses on creating oral small molecule drugs that aim to achieve the efficacy and specificity typically associated with biologic and peptide drugs, while addressing the limitations inherent to these traditional therapies. By integrating cutting-edge scientific techniques, Structure Therapeutics seeks to provide differentiated therapeutic solutions that enhance patient outcomes.

Summarized from source with an LLMView SourceSector: Finance

Latest Results ():

Summarized from source with an LLMView Source

Key figures

198%1Y
89.1%3Y
%5Y

Performance

93.8%1Y
91.1%3Y
88.8%5Y

Volatility

Market cap

3705 M

Market cap (USD)

Daily traded volume (Shares)

471,769

Daily traded volume (Shares)

1 day high/low

28.72 / 26.04

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.50

8 votes
Performance:
starstarstarstarstar
3.11
Innovation:
starstarstarstarstar
4.33
Society:
starstarstarstarstar
4.11
Nature:
starstarstarstarstar
3.67
Bastien Romanens
Switzerland, 02 Nov 2025
star star star star star
-
Virgil Zhu
UK, 27 Oct 2025
star star star star star
really depends on the news about clinical trials
****** Panggabean
UK, 26 Oct 2025
star star star star star
Strong innovation and a solid cash position, but the stock has been under pressure as R&D costs rise and profitability remains distant. The company’s GLP-1 pipeline offers promise, yet market sentiment reflects uncertainty about near-term returns.

EQUITIES OF THE SAME SECTOR

First Interstate Bancsystem Inc
First Interstate Bancsystem Inc First Interstate Bancsystem Inc Valor: 11165896
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.71%USD 38.02
First Hawaiian Inc
First Hawaiian Inc First Hawaiian Inc Valor: 33260134
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.73%USD 27.47
NorthWestern Energy Group Inc
NorthWestern Energy Group Inc NorthWestern Energy Group Inc Valor: 1988893
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.80%USD 70.65
Unum Group
Unum Group Unum Group Valor: 822820
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.69%USD 89.85
Empire Co Ltd
Empire Co Ltd Empire Co Ltd Valor: 687330
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.70%CAD 50.01
IndusInd Bank Ltd.
IndusInd Bank Ltd. IndusInd Bank Ltd. Valor: 1353223
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.19%INR 1,008.20
Wells Fargo & Co
Wells Fargo & Co Wells Fargo & Co Valor: 966021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.08%USD 87.45
TVS Holdings Limited
TVS Holdings Limited TVS Holdings Limited Valor: 19411238
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.44%INR 14,626.40
The Scotts Miracle-Gro Co
The Scotts Miracle-Gro Co The Scotts Miracle-Gro Co Valor: 968945
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.39%USD 62.03
Broadstone Net Lease Inc
Broadstone Net Lease Inc Broadstone Net Lease Inc Valor: 110527344
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.93%USD 20.65